Gastroenterology

Comparison of reference Infliximab and a Biosimilar (CT-P13) in Crohn's Disease (CME/CE)




(MedPage Today) — Analysis of real-world data show that CT-P13 is equivalent to infliximab in infliximab-naive patients with CD

Source link




Related posts

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma

Newsemia

Drinking More Coffee Tied to Lower Risk for Gallstone Disease

Newsemia

AMA president advocates for more equitable future in medicine

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy